Combination therapy can delay resistance of lung cancer cells retrieved 16 April 2024 from https://medicalxpress.com/news/2024-04-combination-therapy-delay-resistance-lung.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Sep 11, 2023Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study findsIn a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Source: NewsMedical - 🏆 19. / 71 Read more »
Study finds immunotherapy combination before surgery improves outcomes for patients with pancreatic cancerA pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.
Source: medical_xpress - 🏆 101. / 51 Read more »
Combination treatment is well-tolerated, shows antitumor effects in KRAS G12C-mutated metastatic colorectal cancerCombining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Source: medical_xpress - 🏆 101. / 51 Read more »
Targeting vulnerability in B-cell development leads to novel drug combination for leukemiaDespite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.
Source: medical_xpress - 🏆 101. / 51 Read more »
Biologic drug-device combination immunotherapy for metastatic prostate cancer patientsSYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results reported at the American Association for Cancer Research (AACR)...
Source: medical_xpress - 🏆 101. / 51 Read more »